NEOPROL

Company Overview

Snapshot

Founded in August 2014, NEOPROL operates with 1–10 employees. The company has secured funding across one disclosed round from one investor.

Business overview

NEOPROL is a Health Tech & Life Sciences company focused on developing advanced drug formulations for anesthesia. The company's core product, NP-09, is an improved and novel bioequivalent of propofol, currently in preclinical development. NEOPROL serves the pharmaceutical and healthcare provider markets globally, leveraging nanotechnology in its drug design and development efforts.

Company Intelligence Q&A

What is NEOPROL's primary focus?

NEOPROL specializes in the development of new formulations for anesthesia drugs, particularly an improved bioequivalent of propofol.

What is NP-09?

NP-09 is NEOPROL's advanced preclinical development, an improved formulation and novel bioequivalent of propofol, demonstrating superiority over Diprivan.

When was NEOPROL founded?

NEOPROL was founded in August 2014.

What is the current development stage of NEOPROL's product?

NEOPROL's product, NP-09, is currently in the R&D stage, specifically advanced preclinical development.